At a glance
| Known as | ALKS 7290 |
|---|---|
| Sponsor | Alkermes |
| Mechanism | Orexin receptor agonist |
| Stage | Phase 1 |
| Indications | ADHD |
| Registered trials | 0 |
| Last verified | 4 Aug 2026 |
Where it stands
ALKS 7290 points the orexin mechanism at attention-deficit hyperactivity disorder. It is the furthest any programme in this class strays from sleep medicine, and the clearest sign that sponsors see orexin signalling as a lever on wakefulness and attention generally rather than on narcolepsy alone.
It sits at Phase 1 on Alkermes' own pipeline page and is not yet listed on ClinicalTrials.gov under this compound name.
ALKS 7290 — common questions
What is ALKS 7290 for?
Attention-deficit hyperactivity disorder, according to Alkermes' pipeline page.
What phase is ALKS 7290 in?
Phase 1. It is not yet listed on ClinicalTrials.gov under this compound name, so Alkermes' pipeline page is the only public source.
Source
This entry was last checked against its primary source on 4 Aug 2026: https://www.alkermes.com/research-and-development/pipeline
Found something out of date? Send a correction with a primary source and it will be fixed.
Get told when this changes
One email when ALKS 7290 changes phase, reads out, or hits a regulatory milestone.
One email per real change. No tracking pixels, no list rental, one-click unsubscribe.